Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroPaceNPCE 70 Days Inventory is 405.10 as of Jun. 2026, which is 67% above its 10-year median of 242.71. GuruFocus rates NPCE with a GF Score™ of 70/100 and a GF Value™ of $12.60 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 786 Medical Devices & Instruments companies, NeuroPace ranks worse than 80.15% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). NeuroPace's Average Total Inventories for the
three
months ended in Jun. 2026 was $17.40 Mil. NeuroPace's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $3.92 Mil.
Hence, NeuroPace's Days Inventory for the
three
months ended in Jun. 2026 was 405.10.
The historical rank and industry rank for NeuroPace's Days Inventory or its related term are showing as below:
NPCE'
s Days Inventory Range Over the Past 10 Years
Min: 215.58 Med: 242.71 Max: 312.44
Current: 312.44
During the past 7 years, NeuroPace's highest Days Inventory was 312.44. The lowest was 215.58. And the median was 242.71.
NPCE's Days Inventory is ranked worse than 80.15% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 176.135
vs NPCE: 312.44
NeuroPace's Days Inventory
declined
from Jun. 2025 (415.26) to Jun. 2026 (405.10).
Inventory Turnover measures how fast the company turns over its inventory within a year.
NeuroPace's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.23.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NeuroPace's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.76.
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
NeuroPace's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
NeuroPace's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
NeuroPace Days Inventory Related Terms
NeuroPace Days Inventory Historical Data
* Premium members only.
The historical data trend for NeuroPace's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NPCE vs KIDS, VREX, OFIX: Days Inventory Comparison
For the Medical Devices subindustry, NeuroPace's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Days Inventory distribution charts can be found below:
* The bar in red indicates where NeuroPace's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroPace (NPCE) has a Days Inventory of 405.10 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on NeuroPace and its competitors. This is 67% above median its historical median of 242.71. Over the past decade, NeuroPace's Days Inventory has ranged from 215.58 to 312.44. According to the industry distribution chart, NeuroPace ranks #630 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 80.2%.
Is NeuroPace's Days Inventory too high?
NeuroPace's current Days Inventory of 405.10 is 67% above median its 10-year median of 242.71. Over the past 10 years, this metric has ranged from a low of 215.58 to a high of 312.44. The Medical Devices & Instruments industry median Days Inventory is 176.14. NeuroPace's value of 405.10 is 130% above this industry median. Based on the distribution chart, NeuroPace ranks #630 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroPace has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's Days Inventory compare to KIDS and VREX?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #630 out of 786 companies for Days Inventory. This places NeuroPace in the lower half of its industry. The industry median Days Inventory is 176.14. NeuroPace's value of 405.10 is 130% above this benchmark. Historically, NeuroPace's own Days Inventory has ranged from 215.58 to 312.44 over the past decade. While the company's 10-year median is 242.71 vs. the industry median of 176.14, NeuroPace has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 176.14, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroPace's current Days Inventory of 405.10 is 130% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on NeuroPace and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 176.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroPace's current Days Inventory is 405.10, which is 67% above median its own 10-year median of 242.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.60, compared to a current price of $14.04 — trading 11.4% above its estimated fair value. The current Days Inventory is 405.10, which is 67% above median its 10-year median of 242.71 and 130% above the Medical Devices & Instruments industry median of 176.14. NeuroPace's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For NeuroPace (NPCE), the current Days Inventory is 405.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $14.04 is trading 11.4% above its estimated GF Value™ of $12.60.
GuruFocus considers NeuroPace to be Modestly Overvalued.
Key valuation signals for NPCE:
Days Inventory: 405.10 (67% above median its 10-year median of 242.71)
GF Value™: $12.60 vs. price of $14.04 (11.4% above fair value)
Industry Position: 130% above the Medical Devices & Instruments median (#630 of 786)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
70GF Score
Get the complete analysis for NPCE
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
